Small Molecules
9 April 2013
ArQule’s Novel AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase 1 Trial9 April 2013
Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir for the Treatment of Hepatitis C8 April 2013
NewLink Genetics Presents Preclinical Data on New IDO Pathway Inhibitor, NLG919, at AACR 2013 Annual Meeting8 April 2013
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration8 April 2013
MethylGene Presents Preclinical Data on MG516 at the American Association for Cancer Research Annual Meeting6 April 2013
AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis6 April 2013
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases4 April 2013
Aragon Announces First Patient Dosed in Phase I Study of ARN-810 in Estrogen Receptor Positive Breast Cancer4 April 2013
Beech Tree Labs Announces Successful Completion of IND Phase 1/2a Oral Herpes Clinical Trial1 April 2013
Cytokinetics Announces Initiation of First-Time-in-Humans, Phase I Clinical Trial of CK-21271071 April 2013
U.S. FDA Approves INVOKANA™ (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes1 April 2013
ArQule Regains Worldwide Rights to AKT ProgramNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports